Search - tctmd.com

Displaying 1 - 11 of 11

Sort: Relevancy | Date

News Daily News

Prehospital Troponin Testing With EMS Input Could Save a Lot of Money

Michael O'Riordan

February 07, 2023

News

LGBTQ+ People at Risk of Worse CV Health, Subpar Care: AHA

Caitlin E. Cox

June 24, 2022

News Daily News

Financial Strain Ups Risk of Death After Acute MI in the Elderly

L.A. McKeown

February 25, 2022

News Features

As COVID-19 Drags on, the Cardiology Fallout May Haunt for Years

Caitlin E. Cox

December 16, 2021

News Daily News

AHA Policy Statement Focuses on Gaps in STEMI Systems of Care

L.A. McKeown

October 18, 2021

News Daily News

Food Insecurity Common Among Patients With ASCVD

Michael O'Riordan

August 18, 2021

News Daily News

ASCVD and Cancer Diagnoses Pose Potentially Deadly Costs to Patients

Caitlin E. Cox

June 16, 2021

News Daily News

Longer Work Hours After MI Tied to Higher Risk of Recurrent Events

Caitlin E. Cox

April 01, 2021

News Daily News

Stress Cardiomyopathy Up in Ohio—but Not Directly Due to COVID-19

Yael L. Maxwell

July 13, 2020

News Daily News

Skyrocketing Costs of CVD Will Be Amplified by Informal Caregiving: AHA

Shelley Wood

April 09, 2018

News Industry News

Novartis' new heart failure medicine LCZ696 approved by FDA to reduce risk of cardiovascular death and heart failure hospitalization; now called Entresto™ (sacubitril-valsartan)

July 07, 2015

Advertisement

Prehospital Troponin Testing With EMS Input Could Save a Lot of Money

LGBTQ+ People at Risk of Worse CV Health, Subpar Care: AHA

Financial Strain Ups Risk of Death After Acute MI in the Elderly

As COVID-19 Drags on, the Cardiology Fallout May Haunt for Years

AHA Policy Statement Focuses on Gaps in STEMI Systems of Care

Food Insecurity Common Among Patients With ASCVD

ASCVD and Cancer Diagnoses Pose Potentially Deadly Costs to Patients

Longer Work Hours After MI Tied to Higher Risk of Recurrent Events

Stress Cardiomyopathy Up in Ohio—but Not Directly Due to COVID-19

Skyrocketing Costs of CVD Will Be Amplified by Informal Caregiving: AHA

Novartis' new heart failure medicine LCZ696 approved by FDA to reduce risk of cardiovascular death and heart failure hospitalization; now called Entresto™ (sacubitril-valsartan)

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content